Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 1:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 1,235 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Sars-CoV2 Clear all
Terminated Phase 2 Interventional Results available

Novel Agents for Treatment of High-risk COVID-19 Positive Patients

NCT04374019
View directory record Official record
Conditions
COVID, Sars-CoV2
Interventions
Ivermectin, Camostat Mesilate, Artemesia annua, Artesunate
Drug · Dietary Supplement
Lead sponsor
Susanne Arnold
Other
Eligibility
18 Years to 99 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Oct 24, 2026, 1:43 PM EDT
Completed Phase 3 Interventional Results available

Colchicine/Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial

NCT04472611
View directory record Official record
Conditions
SARS-CoV-2
Interventions
Standard of Care (SOC) and Colchicine+Rosuvastatin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
Bridgeport, Connecticut • Greenwich, Connecticut • New Haven, Connecticut + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 24, 2026, 1:43 PM EDT
Completed Phase 2 Interventional Results available

Smell in Covid-19 and Efficacy of Nasal Theophylline

NCT04789499
View directory record Official record
Conditions
Covid19, Anosmia, Olfactory Disorder, Covid-19 Pandemic, SARS-CoV-2 Infection, Hyposmia, Ageusia, Hypogeusia
Interventions
Theophylline Powder, Placebo Comparator
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Oct 24, 2026, 1:43 PM EDT
Recruiting Phase 3 Interventional

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

NCT06631287
View directory record Official record
Conditions
Long COVID, Sars-CoV-2 Infection, Coronavirus Infections, COVID-19
Interventions
Baricitinib, Placebo
Drug · Other
Lead sponsor
Wes Ely
Other
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
17
States / cities
Tucson, Arizona • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 24, 2026, 1:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)

NCT04679909
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AdCOVID, Placebo
Biological · Other
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
6
States / cities
Hialeah, Florida • Melbourne, Florida • Peoria, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 24, 2026, 1:43 PM EDT
Terminated No phase listed Observational

Efficacy of COVID-19 Vaccination in Patients With Multiple Sclerosis Treated With Immune Modulating Medication

NCT04796584
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Analysis of cell-mediated and antibody-mediated immunity to SARS-CoV-2 virus
Other
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Oct 24, 2026, 1:43 PM EDT
Terminated Phase 3 Interventional

Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada)

NCT04421664
View directory record Official record
Conditions
Corona Virus Infection, SARS-CoV Infection, Coronavirus
Interventions
Hydroxychloroquine, Placebo oral tablet
Drug
Lead sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 24, 2026, 1:43 PM EDT
Completed Not applicable Interventional

Fully Remote, Telehealth-based Ketogenic Metabolic Therapy for Long COVID

NCT07745699
View directory record Official record
Conditions
Long COVID Fatigue
Interventions
Ketogenic Metabolic Therapy, Lifestyle Intervention
Other · Behavioral
Lead sponsor
National University of Natural Medicine
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 24, 2026, 1:43 PM EDT
Completed No phase listed Observational

Advanced Endoscopy During COVID-19

NCT04385147
View directory record Official record
Conditions
Cholangitis, Secondary Biliary, Cholangiocarcinoma, Obstructive Jaundice, Pancreas Cancer, COVID-19, SARS-CoV-2
Interventions
Endoscopic management according to standard of care
Other
Lead sponsor
Al-Azhar University
Other
Eligibility
Not listed
Enrollment
670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Albertson, New York
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Oct 24, 2026, 1:43 PM EDT
Not listed No phase listed Observational

Long COVID-19 and MAB Study

NCT05508295
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
MultiCare Health System Research Institute
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 24, 2026, 1:43 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines

NCT04889209
View directory record Official record
Conditions
COVID-19
Interventions
Ad26.COV2.S, BNT162b2, mRNA-1273, mRNA-1273.211, mRNA-1273.222, SARS-CoV-2 rS/M1
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
867 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
10
States / cities
Decatur, Georgia • Baltimore, Maryland • New York, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2025 · Synced Oct 24, 2026, 1:43 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age

NCT07300839
View directory record Official record
Conditions
COVID-19, SARS-COV-2 Infection
Interventions
BNT162b2 Vaccine, Placebo
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
50 Years to 64 Years
Enrollment
5,240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
196
States / cities
Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 148 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 24, 2026, 1:43 PM EDT
Completed No phase listed Observational

A Study to Assess Infection Rate of Severe Acute Respiratory Syndrome - CoronaVirus 2 (SARS-CoV-2) and It's Affect on Quality of Life in Adult Volunteers in Lake County, Illinois

NCT04611230
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome - CoronaVirus 2 (SARS-CoV-2)
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
1,007 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Oct 24, 2026, 1:43 PM EDT
Completed Not applicable Interventional Results available

Asthma in Families Facing Out-of-pocket Requirements Due to COVID-19

NCT04613739
View directory record Official record
Conditions
Asthma
Interventions
insurance navigation
Behavioral
Lead sponsor
Harvard Pilgrim Health Care
Other
Eligibility
4 Years to 64 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Wellesley, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 24, 2026, 1:43 PM EDT
Not listed No phase listed Observational

Genetic Mechanisms Underlying SARS-CoV-2 Infection and the Impact of COVID-19 on Cognitive Function

NCT04506229
View directory record Official record
Conditions
Covid19
Interventions
Whole exome sequencing
Genetic
Lead sponsor
Texas Cardiac Arrhythmia Research Foundation
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Oct 24, 2026, 1:43 PM EDT
Not listed Phase 1 Interventional

Stem Cell Study for Long COVID-19 Neurological Symptoms

NCT06156241
View directory record Official record
Conditions
Post-Acute COVID-19 Syndrome
Interventions
Stem Cell
Biological
Lead sponsor
Charles Cox
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Oct 24, 2026, 1:43 PM EDT
Completed Early Phase 1 Interventional

COVID-19 Convalescent Plasma (CCP) Transfusion

NCT04412486
View directory record Official record
Conditions
COVID-19
Interventions
COVID Convalescent Plasma
Biological
Lead sponsor
Gailen D. Marshall Jr., MD PhD
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 24, 2026, 1:43 PM EDT
Completed No phase listed Observational

Nurses Caring for Patients With Covid-19

NCT06012539
View directory record Official record
Conditions
Nurse, in Northern New Jersey, Providing Care to Adults With Covid-19
Interventions
Qualitative (interviews)
Other
Lead sponsor
Atlantic Health System
Other
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Timeline
2020 – 2022
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 24, 2026, 1:43 PM EDT
Completed Phase 2 Interventional Results available

Paxlovid for Treatment of Long Covid

NCT05576662
View directory record Official record
Conditions
Post-acute Sequelae of SARS-CoV-2 Infection, Long COVID
Interventions
Nirmatrelvir, Placebo, Ritonavir
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 24, 2026, 1:43 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia

NCT04369469
View directory record Official record
Conditions
COVID-19 Severe Pneumonia, Acute Lung Injury, Acute Respiratory Distress Syndrome, Pneumonia, Viral
Interventions
Ravulizumab, BSC
Biological · Other
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
24
States / cities
Little Rock, Arkansas • Los Angeles, California • Orange, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Oct 24, 2026, 1:43 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis

NCT04948203
View directory record Official record
Conditions
Pulmonary Fibrosis, COVID-19 Pneumonia, Long COVID
Interventions
Sirolimus
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 24, 2026, 1:43 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID

NCT06161688
View directory record Official record
Conditions
Long COVID, Post Acute Sequelae of COVID-19, Post-Acute COVID-19
Interventions
Ensitrelvir, Placebo
Drug · Other
Lead sponsor
Timothy Henrich
Other
Eligibility
18 Years to 69 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 24, 2026, 1:43 PM EDT
Completed Phase 2 Interventional Results available

Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19

NCT04391179
View directory record Official record
Conditions
COVID, Corona Virus Infection, Covid-19, SARS-CoV-2 Infection
Interventions
Dipyridamole 100 Milligram(mg), Placebo oral tablet
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Oct 24, 2026, 1:43 PM EDT
Suspended No phase listed Observational Accepts healthy volunteers

Validation of HyperDetector for SARS-CoV-2

NCT05124496
View directory record Official record
Conditions
SARS-COV2 Infection
Interventions
Screening Device
Device
Lead sponsor
HyperSpectral APD
Industry
Eligibility
5 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Alexandria, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Oct 24, 2026, 1:43 PM EDT